This study was undertaken to investigate the presence of autoantibodies in patients with chronic viral hepatitis B and C, before, during and after interferon-alpha (IFN-alpha) therapy and to study their relation to dose and type of IFN-alpha and response to treatment. Fifty patients with chronic hepatitis were divided in two groups, a control-group of 21 patients (10 type B and 11 type C) who were followed for 6 months without treatment and an IFN-group consisting of 29 patients (8 type B and 21 type C) who received IFN therapy for 6 months. Serum samples were tested for a range of antibodies at the start of the study, during therapy and at the end of the 6 month period. Antibodies tested for included: antinuclear, smooth muscle, antimitochondrial, parietal cell and thyroid microsomal. Four (8%) of the total patient group had autoantibodies at the beginning of the study (two in each group). During the follow-up period no patient in the control group developed antibodies compared with 3 (11%) patients in the treatment group. Autoantibodies developed in patients treated with higher doses of IFN and were found in those patients who tended to show a poor response to IFN-therapy. Further studies are needed to establish the relationship between poor response to IFN-alpha and development of autoantibodies.

Background: Viral hepatitis C is the second leading cause of hepatocellular carcinoma after hepatitis B in Africa and Togo in particular. The advent of direct acting antivirals has revolutionized the care and prognosis of patients infected with hepatitis C virus (HCV). Objective: To evaluate the sustained virological response (SVR) 12 weeks after oral treatment without interferon in HCV infected patients with genotypes 1 and 2. Patients and Method: Descriptive and analytical study based on the retrospective collection of data in the hepatogastroenterology unit of the University Hospital Campus of Lome (Togo) from July 11, 2016 to April 22, 2018. All patients who had a chronic viral hepatitis C with viral replication, naive, regardless of the genotype, regardless of the degree of liver fibrosis, and who had completed their treatment with direct-acting antivirals were included. Results: We recruited 84 patients, 60 of whom were infected with HCV genotype 2 (71.43%) and 24 with HCV genotype 1 (28.57%). There were 58 men and 26 women (sex ratio: 0.45). In HCV genotype 1 patients, the median age was 54.29 years and Sofosbuvir/Ledipasvir was the most used combination (62.50%). In HCV genotype 2 patients, the median age was 54.5 years and Sofosbuvir associated with Ribavirin was the most used treatment (81.66%). The virological response at the end of treatment was 100% (genotype 1) and 93.30% (genotype 2). The SVR 12 was 100% (genotype 1) and 91.70% (genotype 2). Five patients were in treatment failure (genotype 2). Conclusion: Direct-acting antivirals were effective in our patients. The rate of sustained virological response was above 90%.

Clinical trials have shown the safety and efficacy of Hepatitis B (HB) vaccination, but it is well known that host and immunization factors can affect the response to HB vaccine. In order to assess the importance of some of these factors we evaluated the immune response of 86 health care workers who received three doses of H-B-Vax intramuscularly (deltoid), at days 0, 30 and 180. Serum samples were taken after each dose and anti-HBs antibodies were determined by quantitative radioimmunoassay. The results showed that males had a diminished immune response to the first dose of HB vaccine (31.7% x 53.3%, p < 0.05) and had geometric mean titers (GMT) of anti-HBs lower than females at the end of the vaccination program (2109.4 x 2453.8, p > 0.05). Smokers had a lower rate of seroconversion after the first dose (29.7% x 53.1%, p < 0.05) and reached lower GMT (2015.2 x 2453.8, p > 0.05) than non-smokers. There were no statistically significant differences between individuals younger or older than 35 years old, in either immunological response of level of anti-HBs.

The authors developed a comparative study of the various methods of assessment of immune response to Hepatitis B vaccine. Eighty-six health care professionals underwent a vaccination programme with three doses of plasma-derived vaccine against Hepatitis B (H-B-Vax, Merck, Sharp & Dohme) given intramuscularly. Assessment of immune response was carried out three months after the end of the programme, by radioimmunoassay (RIA) and enzyme immunoassay (EIA). The results showed that the semi-quantitative assessment of Anti-HBs antibodies by RIA or EIA was perfectly comparable to the reference method (quantitative determination of antibodies by RIA). In view of these findings, the authors suggest a standardization of assessment of immune response to the vaccine, thus permitting correct planning of booster doses and easier comparison between different studies.

The authors studied 23 chronic carriers of HBsAg, to classify them in terms of serology, histopathologic findings and behaviour of markers HBsAg and HBcAg in hepatic tissue. Immunohistochemical techniques were used to establish possible relations between these parameters. Among patients with positive HBeAg found all exhibited HBcAg in hepatic tissue, but in 16 patients in which HBeAg was negative, liver HBcAg was positive in 3 cases (18.7%). No correlation was found between the HBeAg system/anti-HBe and histopathologic findings because chronic active hepatitis was observed in 6/8 anti-HBe positive patients (75%). These findings suggest that, the evaluation of chronic carriers of HBsAg, requires a histologic analysis of the liver, including a tissue research for the virus in addition to a complete serologic study of HBV.